5 results on '"Yago T"'
Search Results
2. Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis.
- Author
-
Nanke Y, Kawamoto M, Yago T, Chiba J, Yamanaka H, and Kotake S
- Subjects
- Arthritis, Rheumatoid surgery, Cell Death drug effects, Cells, Cultured, Drug Therapy, Combination, Fatty Acids, Monounsaturated pharmacology, Fibroblasts drug effects, Fibroblasts metabolism, Fibroblasts pathology, Fluvastatin, Humans, Indoles pharmacology, Synovial Membrane drug effects, Synovial Membrane metabolism, Trypan Blue metabolism, Anti-Ulcer Agents pharmacology, Arthritis, Rheumatoid pathology, Diterpenes pharmacology, Synovial Membrane pathology
- Abstract
Fluvastatin (Fluv) is reported to induce apoptosis in rheumatoid arthritis (RA) synoviocytes through the blocking of protein geranylgeranylation. We report here our investigation of whether geranylgeranylacetone (GGA) induces cell death in RA synoviocytes. Synovial tissues were obtained from patients with RA at the time of total knee arthroplasty. Fibroblast-like synoviocytes (FLS) cultured in three passages were used for the experiments. The FLS were then cultured for 48 h in 48-well flat-bottomed plates containing various concentrations of GGA (0.1-4.0 microg/ml) and either 0.1 or 0.5 microM Fluv. We also examined the effect of GGA and Fluv in human fibroblasts from normal skin (CCD-25SK) and FLS from patients with osteoarthritis (OA). Cells demonstrating cell death were counted following trypan blue staining. In the absence of GGA, there was no apparent cell death, as evidence by trypan blue staining. Concentrations of GGA between 0.1 and 4.0 microg/ml induced cell death in RA FLS, but not in skin fibroblasts (CCD-25SK) nor OA FLS. The number of synoviocytes demonstrating cell death induced by 0.1 or 0.5 microM Fluv was significantly higher than that by the medium alone. In summary, we found that GGA induced cell death in RA FLS, suggesting that GGA may be a potential new therapeutic agent for RA as well as osteoporosis.
- Published
- 2009
- Full Text
- View/download PDF
3. Therapeutic efficacy of intravenous cyclophosphamide concomitant with moderate- to high-dose prednisolone in two patients with fasciitis panniculitis syndrome.
- Author
-
Kato T, Nakajima A, Soejima M, Nagai R, Yago T, Tanohara K, Ichida H, Masuda I, Yamada T, Taniguchi A, Akiyama Y, Mimura T, Tsuchida T, Kamatani N, and Hara M
- Subjects
- Adipose Tissue pathology, Aged, Dose-Response Relationship, Drug, Drug Resistance drug effects, Drug Therapy, Combination, Fasciitis pathology, Female, Humans, Injections, Intravenous, Male, Middle Aged, Panniculitis pathology, Respiratory Insufficiency drug therapy, Respiratory Insufficiency physiopathology, Syndrome, Treatment Outcome, Cyclophosphamide therapeutic use, Fasciitis drug therapy, Glucocorticoids therapeutic use, Immunosuppressive Agents therapeutic use, Panniculitis drug therapy, Prednisolone therapeutic use
- Abstract
Fasciitis panniculitis syndrome (FPS) has been proposed as a new category of 'fasciitis' and includes the well-established eosinophilic fasciitis (EF). Unlike EF, FPS exhibits inconsistent eosinophilia and/or eosinophilic infiltration of the lesions. Principal histological FPS findings include dermal thickening, inflammation and thickening of the subcutaneous fat tissue, fibrous thickening of the fascia and inflammation of the adjacent muscle. FPS is commonly resistant to corticosteroids, and cimetidine is effective in approximately 80% of FPS patients. A new therapy for FPS is required for cases refractory to treatment or intolerant to cimetidine because of adverse drug reaction. In this report, two FPS patients were resistant to corticosteroids. Both received intravenous cyclophosphamide (IVCY) concomitant with moderate- to high-dose prednisolone (PSL), and this effectively treated the induration of the FPS lesions. Patient 1 was a 50-year-old woman who had been diagnosed with fasciitis following en bloc muscle biopsy of the thigh. She had been treated with high-dose PSL for 6 years, but the fasciitis was refractory. Induration of the neck, thorax and thighs resulted in impaired neck rotation, restrictive respiratory failure and impaired walking. A diagnosis of FPS was made by re-assessing the en bloc muscle biopsy. Although PSL (40 mg/day) for 18 days was ineffective, the addition of IVCY (400 mg) dramatically improved the disease manifestations. Patient 2 was a 68-year-old man who was diagnosed with fasciitis based on en bloc muscle biopsy of the left foot. He had been treated with PSL for 16 years, but the fasciitis was refractory. He exhibited lower limb induration and a refractory skin ulcer of the left foot. A diagnosis of FPS was made by re-assessing the en bloc muscle biopsy. Although PSL (40 mg/day) for 2 weeks was ineffective, the addition of IVCY (450 mg) improved both the lower limb induration and the skin ulcer. FPS may cause both entrapment vasculopathy of subcutis and perivasculitis of the subcutaneous fat tissue such that the skin ulcer might be closely related with the ischemic mechanism triggered by FPS. According to the clinical courses of our cases, IVCY combined with moderate- to high-dose PSL may be a new therapeutic choice for corticosteroid-resistant FPS patients.
- Published
- 2008
- Full Text
- View/download PDF
4. The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis.
- Author
-
Momohara S, Okamoto H, Yago T, Furuya T, Nanke Y, Kotake S, Soejima M, Mizumura T, Ikari K, and Tomatsu T
- Abstract
The aim of this study was to investigate determinants of reduced bone mineral density (BMD) in postmenopausal women with active rheumatoid arthritis (RA) and to evaluate whether there are common markers of bone loss. We evaluated BMD of the femoral neck using dual-energy X-ray absorptiometry, and the measured biochemical markers included serum bone-specific alkaline phosphatase (BALP), serum osteocalcin (OC), and serum cross-linked N-telopeptidases of type I collagen (NTx). Serum BALP and NTx concentrations were measured by enzyme-linked immunsorbent assay, and OC was measured using an immunoradiometric assay. One hundred and forty postmenopausal Japanese women who had not received treatment with bisphosphonates or hormone replacement therapy were entered into the study. Thirty-four patients (41.0%) had femoral osteopenia (T score -1 to -2.5) and 23 patients (27.7%) had osteoporosis (T < -2.5). The body mass index of patients with normal BMD (T score >or= -1.0) was significantly higher (P < 0.01) than in patients with osteoporosis at the femoral neck. The T score exhibited a significant negative correlation with age and the duration of RA disease. Serum BALP and serum OC, markers of osteoblast function, were negatively related to erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3). However, serum NTx, a marker of resorptive function, exhibited a positive correlation with ESR, CRP, and MMP-3. From these results, this study suggests that generalized bone loss occurs in active RA and is characterized by evidence of bone resorption that is correlated with the high levels of inflammation. Body mass index, disease duration, and high serum NTx level were common risk factors in osteoporosis of postmenopausal women with RA.
- Published
- 2005
- Full Text
- View/download PDF
5. A case of systemic lupus erythematosus presenting transverse myelitis after an episode of meningitis.
- Author
-
Yago T, Tateishi M, Ichikawa N, Furuya T, Sakurai T, Nakajima H, Hara M, and Kamatani N
- Abstract
A 27-year-old woman suffering from systemic lupus erythematosus was admitted because she had motor and sensory palsy of the lower extremities, neck stiffness, and a fever. Cerebrospinal fluid study indicated meningitis, and magnetic resonance imaging revealed cord swelling and high signals at Th9-Th12 levels. Antibiotics treatment led to resolution of the meningeal signs. Intravenous cyclophosphamide and prednisolone resulted in a partial recovery from the transverse myelitis neurological disturbance.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.